Sugi Predict

Sugi Predict / Compounds / Mespirenone

Mespirenone

Mespirenone

SCHEMBL637071

CC(=O)S[C@@H]1CC2=CC(=O)C=C[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H]([C@@H]4C[C@@H]4[C@@]34CCC(=O)O4)[C@H]12

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PGR P06401 11/20 0.48
▸ AR P10275 11/20 0.48
▸ LMNA P02545 5/20 0.48
▸ ABCB11 O95342 2/20 0.48
▸ NR3C1 P04150 2/20 0.48
▸ CHRM2 P08172 2/20 0.48
▸ HTR2B P41595 2/20 0.48
▸ MAPT P10636 2/20 0.48
▸ CYP3A4 P08684 1/20 0.48
▸ NFKB1 P19838 1/20 0.48
▸ HIF1A Q16665 1/20 0.48
▸ ESR1 P03372 1/20 0.48
▸ ABCB1 P08183 1/20 0.48
▸ NR3C2 P08235 1/20 0.48
▸ CYP2C19 P33261 1/20 0.48
▸ ADRA1A P35348 1/20 0.48
▸ OPRK1 P41145 1/20 0.48
▸ ESR2 Q92731 1/20 0.48
▸ SLC47A1 Q96FL8 1/20 0.48
▸ RAB9A P51151 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Mespirenone SCHEMBL18218179 1.00 PGR (0.48) PGRARLMNAABCB11NR3C1
SCHEMBL18218184 0.90 PGR (0.50) PGRARLMNAABCB11NR3C1
Mespirenone SCHEMBL5796167 0.84 PGR (0.61) PGRARLMNAABCB11NR3C1
SCHEMBL11028634 0.83 PGR (0.49) PGRARLMNAABCB11NR3C1
SCHEMBL8002315 0.81 LMNA (0.71) PGRARLMNAABCB11NR3C1
SCHEMBL6706329 0.79 SHBG (0.44) PGRARLMNAABCB11NR3C1
SCHEMBL7793500 0.79 SHBG (0.42) PGRARLMNAABCB11NR3C1
Spirorenone SCHEMBL8002313 0.78 PGR (0.68) PGRARLMNAABCB11NR3C1
Spirorenone SCHEMBL29666355 0.78 PGR (0.68) PGRARLMNAABCB11NR3C1
SCHEMBL18220861 0.77 SHBG (0.46) PGRARLMNAABCB11NR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015061686-A2 RETINOID X RECEPTOR-GAMMA AGONISTS AND RETINOID X RECEPTOR-ALPHA ANTAGONISTS FOR TREATMENT OF CANCER ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) 2015-04-30 — — WO claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 — — US claimed
US-8715735-B2 Stabilised supersaturated solids of lipophilic drugs BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-05-06 — — US claimed
EP-2087883-B1 Stabilised supersaturated solid solutions of steroidal drugs Bayer Pharma AG (DE) 2012-07-25 — — EP claimed
CN-1984644-B Stable supersaturated solids of lipophilic drugs BAYER SCHERING AG 2010-12-08 — — CN claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 — — US claimed
EP-1765290-B1 STABILISED SUPERSATURATED SOLID SOLUTIONS OF STEROIDAL DRUGS BAYER SCHERING PHARMA AG (DE) 2009-09-09 — — EP claimed
EP-2087883-A1 Stabilised supersaturated solid solutions of steroidal drugs Bayer Schering Pharma Aktiengesellschaft (DE) 2009-08-12 — — EP claimed
US-20090023639-A1 Methods of Treatment IMPERIAL INNOVATIONS LIMITED (GB) 2009-01-22 — — US claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 — — CN claimed
US-20060018937-A1 Steroid kit and foamable composition and uses thereof FOAMIX LTD. 2006-01-26 — — US claimed
WO-2005087199-A2 STABILISED SUPERSATURATED SOLID SOLUTIONS OF STEROIDAL DRUGS SCHERING AKTIENGESELLSCHAFT (DE) 2005-09-22 — — WO claimed
US-20050207990-A1 Stabilised supersaturated solids of lipophilic drugs BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2005-09-22 — — US claimed
WO-2004041288-A1 HORMONE REPLACEMENT THERAPY WITH DROSPIRENONE SCHERING AKTIENGESELLSCHAFT (DE) 2004-05-21 — — WO claimed
US-20040087563-A1 Hormone replacement therapy with cardiovascular protection using antialdosteronic progestins SCHERING AKTIENGESELLSCHAFT (DE) 2004-05-06 — — US claimed
EP-1336602-A1 Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases Scaramuzzino, Giovanni (IT) 2003-08-20 — — EP claimed
EP-1121111-A2 COMPOUNDS FOR THE TREATMENT OF WEIGHT LOSS IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2001-08-08 — — EP claimed
WO-2000021509-A2 METHODS OF TREATMENT IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2000-04-20 — — WO claimed
US-5348729-A Administering antagonists, measuring hormone level THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1994-09-20 — — US claimed
WO-1993022685-A1 EVALUATIVE MEANS FOR DETECTING INFLAMMATORY REACTIVITY THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1993-11-11 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060018937-A1 Steroid kit and foamable composition and uses thereof KIT, GK, HSD17B7 PGR 114/4885AR 27/4885LMNA 1235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.